Abstract: In one illustrative example, a controller for use in a private mobile network may determine network service requirements for an industrial device. The controller may select, from a set of network slices, a subset of network slices having network service requirement configurations that most closely support the network service requirements. Each network slice of the set may be associated with an affinity ranking value that is indicative of a service performance of the network slice for industrial device operation in a cell or a zone associated with a zone or security level value assigned to the industrial device. The controller may identify, from the subset of network slices, a selected network slice associated with a best affinity ranking value for the zone or security level value assigned to the industrial device. The controller may assign the selected network slice and associated service parameters for the communications of the industrial device.

Abstract: A monoclonal antibody which binds a human endothelial type plasminogen activator inhibitor (PAI-1) produced by dexamethasone-treated human HT-1080 fibrosarcoma cells may be used, inter alia, for determining PAI-1 protein abundance in tumor tissue or a sample of a body fluid. Measurements of this parameter may be useful in predicting the presence or metastasis of a tumor, or of predicting the progression of a known malignant tumor.

Abstract: a monoclonal antibody which binds a human endothelial type plasminogen activator inhibitor (PAI-1) produced by dexamethasone-treated human HT-1080 fibrosarcoma cells may be used, inter alia, for determining PAI-1 protein abundance in tumor tissue or a sample of a body fluid. Measurements of this parameter may be useful in predicting the presence or metastasis of a tumor, or of predicting the progression of a known malignant tumor.

Abstract: In a method of producing monoclonal antibodies against endothelial type plasminogen activator inhibitor and immunologically similar inhibitors myeloma cells are fused with antibody-producing cells obtained from mammals which have been immunized with said plasminogen activator inhibitor or with antibody-producing cells, which in vitro have been immunized with said plasminogen activator inhibitor and the hybridomas producing antibodies against the above mentioned inhibitor are selected. The antibody-producing cells are preferably spleen cells or lymph node cells, most preferably spleen cells, obtained from mice immunized with the above mentioned inhibitor.